Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Vård & Omsorg |
NEWS RELEASE
Copenhagen, Denmark, 31 October 2025, Brain+ A/S (Nasdaq First North: BRAINP)
Brain+ A/S (“Brain+” or the “Company”) has updated its communication policy to better reflect the Company’s current growth phase and the significant progress it is achieving, launching Ayla, its dementia care platform, in the UK health and care market.
As of 1st November 2025, the Board and Executive Management of Brain+ has decided to transition to monthly trading updates, accumulating orders received in the past month.
While it remains important to keep investors informed on the progress achieved by the company, it understands that to publish every order is not helpful, especially as orders of varying size are now received on a frequent basis.
However, when the Company receives an order of significant strategic importance in terms of size, profile, or within a new market, etc. it will still be disclosed individually upon receipt.
About Brain+
Brain+ A/S is a digital health company listed on Nasdaq First North Growth Market Denmark, building the world’s first scalable dementia care platform. By reducing preparation time, standardising best practice, and supporting staff training, Ayla empowers healthcare professionals to provide more accessible, effective dementia treatment and care. The Company’s flagship product, Ayla – your CST Assistant, is a digital tool designed to support the consistent delivery of Cognitive Stimulation Therapy (CST)—a non-pharmacological, NICE-recommended and clinically proven intervention for people with mild to moderate dementia.
Contact Information
Devika Wood, CEO: +44 7429 280366, devika@brain-plus.com
Otto Rasmussen, CFO, +45 52536886, otto@brain-plus.com